NLRP3 inflammasomes pathway: a key target for Metformin
Inflammopharmacology · 2025
DOI: 10.1007/s10787-025-01702-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Yasamin Hosseini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Toxicology and Pharmacology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Metformin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 199 Literaturangaben.
Abstract (Originalsprache)
Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain containing 3 (NLRP3) is a signaling pathway that is involved in inflammatory cascades, cell survival and the immune response. NLRP3 is activated by cellular damage, oxidative stress, and other factors that stimulate the immune system. Stimulation of NLRP3 induces inflammatory reactions and the production of inflammatory cytokines. These inflammatory mediators are implicated in several diseases. Metformin (MET) is an anti-hyperglycemia agent that is extensively used in clinical practice worldwide due to its high efficiency, safety profile, and affordable price. MET is the only member of biguanide class that is used in clinical practice and a potent AMP-activated protein kinase (AMPK) agonist with proven anti-inflammatory characteristics. Due to its anti-inflammatory properties, MET is considered to be effective against diseases that have an inflammatory background, and the NLRP3 pathway is involved in the pathophysiology of these disorders. In this review, we have evaluated the evidence if MET can affect this pathway and its utility for future therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Toxicology and Pharmacology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
- School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.
- Department of Toxicology and Pharmacology, School of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Med…
- Royal College of Surgeons in Ireland, PO Box 15503, Adliya, Bahrain.
Zitieren
APA
Hosseini, Y., Niknejad, A., Sabbagh Kashani, A., Gholami, M., Roustaie, M., Mohammadi, M., Momtaz, S., Atkin, S. L., Jamialahmadi, T., Abdolghaffari, A. H., & Sahebkar, A. (2025). NLRP3 inflammasomes pathway: a key target for Metformin. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01702-4
Vancouver
Hosseini Y, Niknejad A, Sabbagh Kashani A, Gholami M, Roustaie M, Mohammadi M, et al. NLRP3 inflammasomes pathway: a key target for Metformin. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01702-4
BibTeX
@article{Hosseini2025,
author = {Hosseini, Yasamin and Niknejad, Amirhossein and Sabbagh Kashani, Ayeh and Gholami, Mahsa and Roustaie, Mahtab and Mohammadi, Mohammad and Momtaz, Saeideh and Atkin, Stephen L and Jamialahmadi, Tannaz and Abdolghaffari, Amir Hossein and Sahebkar, Amirhossein},
title = {NLRP3 inflammasomes pathway: a key target for Metformin},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-025-01702-4}
}
EUVIMED